Osteoporosis in men

Current Opinion in Rheumatology

Volumn 25, Issue 4, 2013, Pages 542-552

  Ebeling, Peter R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bisphosphonates; denosumab; hypogonadism; osteoporosis; strontium ranelate; zoledronic acid

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; DENOSUMAB; ESTRADIOL; HYDROCORTISONE; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PRASTERONE; RISEDRONIC ACID; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BACKACHE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CELIAC DISEASE; CHRONIC LIVER DISEASE; CUSHING SYNDROME; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; FEVER; FRACTURE; HIP FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCIURIA; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FAILURE; KYPHOSIS; MALABSORPTION; MASTOCYTOSIS; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; MYALGIA; OSTEOBLAST; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SMOKING; SPINE FRACTURE; THYROTOXICOSIS; X RAY;

BONE DENSITY CONSERVATION AGENTS; GONADAL STEROID HORMONES; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SEX FACTORS;

EID: 84879884526     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328362164d     Document Type: Review

References (96)

1. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7:407-413. (Pubitemid 27443065)
2. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol 1996; 144:255-263. (Pubitemid 26313502)
3. Chang KP, Center JR, Nguyen TV, Eisman JA. Incidence of hip and other osteoporotic fractures in elderly men and women: Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 2004; 19:532-536. (Pubitemid 41071211)
4. Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996; 6:233-239. (Pubitemid 26171277)
5. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11:1010-1018. (Pubitemid 26200053)
6. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16:87-116.
7. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7:221-227.
8. Khosla S, Lufkin EG, Hodgson SF, et al. Epidemiology and clinical features of osteoporosis in young individuals. Bone 1994; 15:551-555. (Pubitemid 24249214)
9. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24:719-725.
10. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604-610. (Pubitemid 30659471)
11. Orwoll ES, Binkley NC, Lewiecki EM, et al. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010; 46:970-976.
12. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, doubleblind, active-controlled study. J Bone Miner Res 2010; 25:2239-2250.
13. Seeman E, Bianchi G, Khosla S, et al. Bone fragility in men: where are we? Osteoporos Int 2006; 17:1577-1583. (Pubitemid 44477616)
14. Krabbe S, Hummer L, Christiansen C. Longitudinal study of calcium metabolism in male puberty. II. Relationship between mineralization and serum testosterone. Acta Paediatr Scand 1984; 73:750-755. (Pubitemid 15217591)
15. Lorentzon M, Swanson C, Andersson N, et al. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 2005; 20:1334-1341. (Pubitemid 41033517)
16. Ebeling PR. Osteoporosis in men: new insights into aetiology, pathogenesis, prevention and management. Drugs Aging 1998; 13:421-434. (Pubitemid 29002720)
17. Morishima A, GrumbachMM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80:3689-3698.
18. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331:1056-1061. (Pubitemid 24317698)
19. Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987; 106:354-361. (Pubitemid 17029484)
20. Lambert JK, Zaidi M, Mechanick JI. Male osteoporosis: epidemiology and the pathogenesis of aging bones. Curr Osteoporosis Reports 2011; 9:229-236.
21. Nordstrom P, Neovius M, Nordstrom A. Early and rapid bone mineral density loss of the proximal femur in men. J Clin Endocrinol Metab 2007; 92:1902-1908. (Pubitemid 46997208)
22. Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Int 2001; 69:229-234. (Pubitemid 33035394)
23. Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994; 309:691-695. (Pubitemid 24285219)
24. Pietschmann P, Kudlacek S, Grisar J, et al. Bone turnover markers and sex hormones in men with idiopathic osteoporosis. Eur J Clin Invest 2001; 31:444-451. (Pubitemid 32479208)
25. Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908-3915. (Pubitemid 44536863)
26. Khosla S, Riggs BL, Atkinson EJ, et al. Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 2006; 21:124-131. (Pubitemid 43023234)
27. Riggs BL, Melton LJ, Robb RA, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008; 23:205-214. (Pubitemid 351160034)
28. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473:139-146.
29. Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kB legend with bone mineral density in older adults: the Rancho Bernardo Study. Eur J Endocrinol 2007; 156:555-562. (Pubitemid 46796522)
30. Riancho JA, Olmos JM, Pineda B, et al. Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication. Eur J Endocrinol 2011; 164:123-131.
31. Papaioannou A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int 2009; 20:507-518.
32. Michaelsson K, Olofsson H, Jensevik K, et al. Leisure physical activity and the risk of fracture in men. PLoS Med 2007; 4:e199.
33. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr 2009; 89:1188-1196.
34. Ebeling PR. Osteoporosis in men. N Engl J Med 2008; 358:1474-1482.
35. Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clinical Endocrinology 2005; 62:64-73. (Pubitemid 40175285)
36. Abbasi AA, Rudman D, Wilson CR, et al. Observations on nursing home residents with a history of hip fracture. Am J Med Sci 1995; 310:229-234. (Pubitemid 26001201)
37. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86:2787-2791. (Pubitemid 32545740)
38. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352:154-164. (Pubitemid 40096612)
39. Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 2001; 54:739-750. (Pubitemid 34208885)
40. Dillon E, Urban R, Angel J, et al. Continuous testosterone administration for 5 months reduces markers of bone turnover in older men. FASEB J 2008; 22:1188.
41. Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002; 167:1952-1956. (Pubitemid 34309635)
42. Grossmann M, Hamilton EJ, Gilfillan C, et al. Bone and metabolic health in patients with nonmetastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust 2011; 194:301-306.
43. Ferrari SL, Deutsch S, Choudhury U, et al. Polymorphisms in the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with variation in vertebral bone mass, vertebral bone size, and stature in whites. Am J Human Genet 2004; 74:866-875. (Pubitemid 38568961)
44. Li W-F, Hou S-X, Yu B, et al. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet 2010; 127:249-285.
45. Maggio D, McCloskey EV, Camilli L, et al. Short-term reproducibility of proximal femur bone mineral density in the elderly. Calcified Tissue Int 1998; 63:296-299. (Pubitemid 28443412)
46. Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAXTM algorithm and Garvan nomogram. Osteoporos Int 2010; 21:863-871.
47. Waddell G, Somerville D, Henderson I, Newton M. Objective clinical evaluation of physical impairment in chronic low back pain. Spine 1992; 17:617-628.
48. Ferrar L, Jiang G, Cawthon PM, et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS Study. J Bone Mineral Res 2007; 22:1434-1441. (Pubitemid 351339688)
49. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
50. Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Mineral Res 2005; 20:579-587. (Pubitemid 40393065)
51. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
52. Ryder K, Bobo Tanner S, Carbone L, et al. Teriparatide is safe and effectively increases bone biomarkers in institutionalized individuals with osteoporosis. J Bone Miner Metab 2010; 28:233-239.
53. Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol 2010; 162:1009-1020.
54. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010; 341:c3691.
55. Lewis JR, Calver J, Zhu K, et al. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011; 26:35-41.
56. Eisman JA, Ebeling PR, Ewald D, et al. Clinical guideline for the treatment of osteoporosis in postmenopausal women and older men. The Royal Australian College of General Practitioners (RACGP); 2010.
57. Vieth R, Chan P-CR, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutrition 2001; 73:288-294. (Pubitemid 32109858)
58. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind placebo study. J Clin Endocrinol Metab 2001; 86:4098-4103. (Pubitemid 32848519)
59. Aminorroaya A, Kelleher S, Conway AJ, et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152:881-886. (Pubitemid 40903579)
60. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the massachusetts male aging study. J Clin Endocrinol Metab 2004; 89:5920-5926. (Pubitemid 39628393)
61. van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Netherlands J Med 1992; 41:259-263.
62. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358-4365. (Pubitemid 26412044)
63. Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776-783. (Pubitemid 19245856)
64. Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386-2390. (Pubitemid 27337844)
65. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503-510. (Pubitemid 38269849)
66. Benito M, Vasilic B, Wehrli FW, et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Mineral Res 2005; 20:1785-1791. (Pubitemid 41361879)
67. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109-122.
68. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; CD001155.
69. Wells GA, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008; CD004523.
70. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25:2267-2294.
71. Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367:1714-1723.
72. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of antifracture efficacy in women. BMC Musculoskeletal Disord 2005; 6:39.
73. Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004; 34:1064-1071. (Pubitemid 38749245)
74. Lespessailles E. Bisphosphonates and glucocorticoid-induced osteoporosis: efficacy and tolerability. Joint Bone Spine 2012. [Epub ahead of print].
75. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. J Rheumatol 2009; 36:1705-1714.
76. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416-424. (Pubitemid 351650576)
77. Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152:621-629.
78. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26:427-431.
79. Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 2006; 355:2278-2281. (Pubitemid 44837776)
80. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799-1809. (Pubitemid 350044800)
81. Eriksen EF, Lyles KW, Colon-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res 2009; 24:1308-1313.
82. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
83. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008-2012. (Pubitemid 36576705)
84. Ryan CW, Huo D, Bylow K, et al. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid. BJU Int 2007; 100:70-75. (Pubitemid 46878544)
85. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourinary Cancer 2007; 5:271-277. (Pubitemid 46867363)
86. Satoh T, Kimura M, Matsumoto K, et al. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone- naive prostate carcinoma. Cancer 2009; 115:3468-3474.
87. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
88. Orwoll E, Teglbjærg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97:3161-3169.
89. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98:592-601.
90. Hiligsmann M, Ben Sedrine W, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int 2013.
91. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86:957-964. (Pubitemid 32322965)
92. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9-17. (Pubitemid 36008334)
93. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005; 16:510-516.
94. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349:1216-1226. (Pubitemid 37152031)
95. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008; 93:3785-3793.
96. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone (1-34)]. Osteoporos Int 2004; 15:992-997. (Pubitemid 40064654)